Breast Cancer Diagnosis, Therapy Differ in Women With Implants

Share this content:
Breast Cancer Diagnosis, Therapy Differ in Women With Implants
Breast Cancer Diagnosis, Therapy Differ in Women With Implants

WEDNESDAY, April 4, 2018 (HealthDay News) -- Method of diagnosis, stage, and treatment are not affected by type of breast implant or anatomic location, according to research published in the April issue of Plastic and Reconstructive Surgery.

Michael Sosin, M.D., from MedStar Georgetown University Hospital in Washington, D.C., and colleagues retrospectively reviewed 48 cases of patients with prior breast augmentation undergoing breast cancer treatment from 2000 to 2013 and 302 propensity-matched controls.

The researchers found that palpable lesions were detected at a smaller size in augmentation patients (P < 0.001) and fewer lesions were detected by screening mammography in augmented patients (P = 0.010). For diagnosis, patients with implants were more likely to undergo an excisional biopsy (P < 0.001) rather than image-guided core needle biopsy (P < 0.001). There was a trend toward earlier staging in augmented patients (P = 0.073). There were higher mastectomy rates and lower rates of breast-conservation therapy (P = 0.023) among augmented patients. Method of diagnosis, stage, and treatment were not affected by implant fill type or anatomic location.

"Our findings may have important implications for patient counseling regarding breast augmentation and breast cancer detection," Sosin said in a statement.

Several authors disclosed financial ties to the medical device industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

CDC: Birth Rate for 10- to-14-Year-Olds at Record Low in 2016

CDC: Birth Rate for 10- to-14-Year-Olds at Record ...

Reduction in birth rates for all race and Hispanic origin groups; largest decline in non-Hispanic blacks

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria

Lower mortality seen with lonafarnib monotherapy after 2.2 years compared with no treatment

About 40 Percent of Men Report Experiencing Weight Stigma

About 40 Percent of Men Report Experiencing Weight ...

Experience of weight stigma associated with increased odds of underweight or obesity

is free, fast, and customized just for you!

Already a member?

Sign In Now »